Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 49Immunoglobulin Light-chain Amyloidosis 6Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Neoplasm, Residual 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Myelodysplastic Syndromes 2Lymphoma 2Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Autoimmune Diseases of the Nervous System 1Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1Anemia, Aplastic 1Amyloidosis 1Acute Kidney Injury 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Proteostasis Deficiencies × daratumumab × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡